

CERTIFICATE OF MAILING
UNDER 37 CFR 1.8(a)

IPW



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MAIL STOP IDS, Commissioner of Patents and Trademarks, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on

28 JAN 2005
HUESCHEN AND SAGE

Deone L. Newton
Dated: 28 JAN 2005

MERZ 35 /dlh

* * * * *

Applicant : Khalid IQBAL and Inge GRUNDKE-IQBAL
Serial No. : 10/622,163
Filed : 17 JUL 2003
Title : NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN
INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF
MICROTUBULE ASSOCIATED PROTEIN *TAU*

* * * * *

Honorable Commissioner of Patents and Trademarks
ALEXANDRIA, VA 22313-1450

COMMUNICATION COVERING TRANSMITTAL OF INFORMATION
DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

Herewith, in accord with the foregoing regulations, please find an Information Disclosure Statement which, it is respectfully submitted, should materially advance and accelerate the prosecution of the above-identified application. Attached hereto is a Form PTO-1449 and copies of the documents listed thereon.

As will be noted, this Information Disclosure Statement calls a number of prior art references, which might be considered relevant, to the attention of the Office. The fact that these are in fact "Prior Art" and/or relevant to the prosecution is, however, not admitted. It is understood that, during examination, the Office will make an independent search and will identify any relevant prior art under 37 CFR § 1.104(a).

Entry of this Information Disclosure Statement into the file of this application, initialing of each reference entry, making all of the references called

to the Office's attention therein of record, and favorable action on the merits of this application are all respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

By: 
G. PATRICK SAGE

Dated: January 28, 2005
Customer No.: 25,666
500 Columbia Plaza
350 East Michigan Ave.
Kalamazoo, MI 49007
(269) 382-0030

Enclosure: Postal Card Receipt
Form PTO-1449 listing references, and copies of each reference.

* * * * *

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR DEFECT IN THE ATTACHED CHECK, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.

PTO-1449	ATTY. DOCKET NO. MERZ 35	SERIAL NO. 10/622,163
LIST OF PRIOR ART CITED BY APPLICANT	APPLICANT Khalid IQBAL, et al.	
SHEET 1 OF 1	FILING DATE 17 JUL 2003	GROUP

U.S. PATENT DOCUMENTS

Exam iner Initial		DOCU- MENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A	5,614,560	25 MAR 1997	Lipton			
	B	5,061,703	29 OCT 1991	Schatton, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANS- LATION	
	C	WO92/17168A	15 OCT 1992	WO			YES	NO
	D	WO01/89448A	29 NOV 2001	WO			YES	
	E	WO99/01416A	14 JAN 1999	WO			YES	

OTHER PRIOR ART

	F	Naskar, Rita et al., "Phenytoin blocks retinal ganglion cell death after partial optic nerve crush", Experimental Eye Research, vol. 74, no. 6, June 2002 (2002-06), pages 747-752
	G	Schuettauf, Frank et al., "Effects of anti-glaucoma medications on ganglion cell survival: The DBA/2J mouse model.", Vision Research, vol. 42, no. 20, September 2002 (2002-09), pages 2333-2337
	H	Wenk et al., "neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites", European Journal of Pharmacology, Amsterdam, NL, vol. 347, 1998, pages 183-187
	I	Naish, Hywel J., et al.: "Effect of low-affinity NMDA receptor antagonists on electrical activity in mouse cortical slices", European Journal of Pharmacology, vol. 443, no. 1-3, 17 MAY 2002 (2002-05-17), pages 79-83
	J	Parsons, C. G. et al: "Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists: In vitro characterisation", Amino Acids (Vienna), vol. 19, no. 1, 2000, pages 157-166
	K	International Search Report for PCT/US03/22362, eleven (11) pages

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.